As a biomarker of liver function, serum alanine aminotransferase (ALT) levels are commonly used to evaluate hepatic inflammation and liver injury in chronic liver diseases, including NAFLD patients [3, 4]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.